INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 421m ago
HOUSE PTR21m ago
SEC 13F21m ago
ROBINHOOD CHAIN21m ago
Public company

NUVBNuvation Bio Inc.

CIK 0001811063

EDGAR filingsOpen in network
Disclosed transactions31
Buys / sells1 / 9
Max Insider Score47
Connections7with evidence

NUVB · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
SP
Sauvage PhilippeChief Financial Officer
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M—
47.7K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    BGR GOVERNMENT AFFAIRSLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Sauvage PhilippeChief Financial Officer · Jun 24, 2026
  • ← Insider ofevidence
    Markel StacyCHIEF PEOPLE OFFICER · Jun 24, 2026
10
MS
Markel StacyCHIEF PEOPLE OFFICER
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M
$60K
34.6K sh
Jun 23, 2026
Jun 24, 2026
traded Jun 23, 2026
+1d
SEC FORM 4

Evidence

28
MS
Markel StacyCHIEF PEOPLE OFFICER
NUVBNuvation Bio Inc.
Open-market sale · 10b5-1 plan
SELL$753K
125.0K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

28
SP
Sauvage PhilippeChief Financial Officer
NUVBNuvation Bio Inc.
Open-market sale · 10b5-1 plan
SELL$286K
47.7K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

14
MS
Markel StacyCHIEF PEOPLE OFFICER
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M$169K
90.4K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

3
MS
Markel StacyCHIEF PEOPLE OFFICER
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M—
34.6K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

7
MS
Markel StacyCHIEF PEOPLE OFFICER
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M—
90.4K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

14
SP
Sauvage PhilippeChief Financial Officer
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M$103K
47.7K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

36
MR
Mashal RobertDirector
NUVBNuvation Bio Inc.
Open-market purchase
BUY$118K
25.0K sh
Jun 9, 2026Jun 11, 2026
traded Jun 9, 2026
+2dSEC FORM 4

Evidence

15
MR
Mashal RobertDirector
NUVBNuvation Bio Inc.
Grant or award
A—
123.4K sh
May 21, 2026May 26, 2026
traded May 21, 2026
+5dSEC FORM 4

Evidence

0
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M—
50.0K sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

19
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Open-market sale · 10b5-1 plan
SELL$251K
50.0K sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

10
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise · 10b5-1 plan
M$97K
50.0K sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

33
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Open-market sale
SELL$80K
10.0K sh
Nov 26, 2025Nov 26, 2025
traded Nov 26, 2025
+0dSEC FORM 4

Evidence

17
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M$36K
10.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

17
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M$36K
10.0K sh
Nov 26, 2025Nov 26, 2025
traded Nov 26, 2025
+0dSEC FORM 4

Evidence

5
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M—
10.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

5
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M—
10.0K sh
Nov 26, 2025Nov 26, 2025
traded Nov 26, 2025
+0dSEC FORM 4

Evidence

33
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Open-market sale
SELL$75K
10.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

17
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M$37K
20.0K sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

37
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Open-market sale
SELL$140K
20.0K sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

5
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M—
20.0K sh
Nov 20, 2025Nov 24, 2025
traded Nov 20, 2025
+4dSEC FORM 4

Evidence

47
HC
Hanley David C.CHIEF TECHNICAL OPERATIONS
NUVBNuvation Bio Inc.
Open-market sale
SELL$1.43M
200.0K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

27
HC
Hanley David C.CHIEF TECHNICAL OPERATIONS
NUVBNuvation Bio Inc.
Option exercise
M$374K
200.0K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

21
HC
Hanley David C.CHIEF TECHNICAL OPERATIONS
NUVBNuvation Bio Inc.
Option exercise
M—
200.0K sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

41
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Open-market sale
SELL$71K
15.0K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

21
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M$28K
15.0K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

5
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M—
15.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

33
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Open-market sale
SELL$77K
15.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

9
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M—
15.0K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

17
LD
Liu DongfangCHIEF MEDICAL OFFICER
NUVBNuvation Bio Inc.
Option exercise
M$28K
15.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Mashal RobertDirector · May 26, 2026
  • ← Insider ofevidence
    Hanley David C.CHIEF TECHNICAL OPERATIONS · Nov 21, 2025
  • ← Insider ofevidence
    Liu DongfangCHIEF MEDICAL OFFICER · Nov 19, 2025

    • Lobbying

    $110K reported · de-duplicated
    2026 Q2 $80K via firms2026 Q1 $30K via firms
    • BGR GOVERNMENT AFFAIRS$30K2026 Q1 · posted Aug 26, 2026 · Health issues
    • BGR GOVERNMENT AFFAIRS$80K2026 Q2 · posted Aug 26, 2026 · Health issues
    • BGR GOVERNMENT AFFAIRS—2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.